∙ Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma.

• Patients will be eligible regardless of the number of prior systemic therapies received.

‣ Cohort 2: Must have a confirmed diagnosis of unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) that is refractory to at least 1 prior line of systemic therapy

• Unresectable disease will be defined by an expert sarcoma surgical onocologist as either (a) low liklihood of obtaining an R0 resection or (b) unacceptable morbidity from a surgical procedure

• Prior systemic therapy in the neoadjuvant or adjuvant setting will count has prior systemic therapy

• Patients who refuse standard of care chemotherapy will be eligible

‣ One (1) lesion at least 1.5cm in size (solitary or aggregate) available for TIL harvesting that has not undergone prior embolization or RT in prior 3 months unless subsequent growth is demonstrated (at least 0.5cm).

⁃ Patients must be ≥ 18 years of age at the time of consent.

⁃ Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

⁃ Patients must have an estimated life expectancy of ≥ 6 months in the opinion of the Investigator.

⁃ Patients must have the following hematologic parameters:

• Absolute neutrophil count (ANC) ≥ 1000/mm3

• Hemoglobin (Hb) ≥ 9.0 g/dL

• Platelet ≥ 100,000/mm\^3 Note: Transfusions or growth factors are not allowed 28 days prior to signing the ICF and continuing through the Screening Period

‣ Patients must have adequate organ function:

• Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (≤ 3 × ULN); patients with liver metastasis ≤ 5 × ULN

• Estimated creatinine clearance (eCrCl) ≥ 40 mL/min using the Cockcroft-Gault formula at Screening

• Total bilirubin ≤ 2 mg/dL

• Patients with Gilbert's syndrome must have a total bilirubin ≤ 3 mg/dL

‣ Patients must be seronegative for the following:

• Human immunodeficiency virus (HIV)-1 or HIV-2 antibodies

• Hepatitis B antigen (HBsAg), hepatitis B core antibody (anti- HBc), or hepatitis C antibody (HCV Ab). Patients with acute or chronic hepatitis infections may be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment.

• Syphilis (Rapid Plasma Reagin \[RPR\] test or venereal disease research laboratory \[VDRL\] test)

• Cytomegalovirus (CMV) IgM antibody titer or PCR assay; and Epstein-Barr virus (EBV) IgM or PCR assay indicating active infection

• Herpes simplex virus (HSV)-1 and HSV-2 IgM serology or PCR assay

‣ Patients who are HSV immunoglobulin M (IgM) or PCR assay positive will need to receive appropriate treatment and become IgM or PCR assay negative prior to starting the NMA-LD pre-conditioning regimen

⁃ Anyone with prior COVID-19 infection must be asymptomatic for \>30 days prior to NMA-LD.

⁃ Patients must have a washout period from prior anticancer therapy(ies) of a minimum duration, as detailed below prior to the first study treatment (ie, start of NMA-LD):

• Targeted therapy: prior targeted therapy with an EGFR, MEK, BRAF, ALK, ROS1, or other-targeted agents (eg, erlotinib, afatinib, dacomitinib, osimertinib, crizotinib, ceritinib, lorlatinib) is allowed provided the washout is a minimum of 14 days or 5 half-lives (whichever is longer) prior to the start of treatment

• Chemotherapy: minimum of 21 days prior to the start of treatment

• Immunotherapy: checkpoint-targeted therapy with an anti PD-1/anti PD-L1, other monoclonal antibodies, or vaccines are allowed, provided the washout is a minimum of 21 days prior to the start of study treatment

‣ Palliative radiation therapy is permitted so long as it does not involve lesions being selected for TIL, or as target or non-target lesions. Washout is not required if all related toxicities have resolved to ≤ Grade 1 as per CTCAE v 5.0.

⁃ Patients must have recovered from all prior anti-cancer therapy-related adverse events (AEs) to ≤ Grade 1 (per Common Terminology Criteria for Adverse Events \[CTCAE\] v 5.0), except for alopecia or vitiligo, prior to enrollment.

• Patients with documented ≥ Grade 2 diarrhea or colitis as a result of previous treatment with immune checkpoint inhibitor(s) must have been asymptomatic for at least 6 months and/or had a normal colonoscopy post-immune checkpoint inhibitortreatment, by visual assessment, prior to tumor resection.

• Patients with immunotherapy-related endocrinopathies (e.g. hypothyroidism) stable for at least 6 weeks and controlled with hormonal replacement are allowed.

‣ Previous surgical procedure(s) is/are permitted provided that wound healing has occurred, all complications have resolved, and at least 14 days have elapsed (for major operative procedures) prior to the tumor resection.

⁃ Patients of childbearing potential (or female partners of male participants) must be willing to take the appropriate precaution to avoid pregnancy or fathering a child for the duration of the study and practice an approved, highly effective method of birth control during treatment and for 12 months after their last dose of IL-2. Approved methods of birth control are as follows:

• Combined (estrogen and progesterone containing) hormonal birth control associated with inhibition of ovulation: oral, intravaginal, transdermal

• Progesterone-only hormonal birth control associated with inhibition of ovulation: oral, injectable, implantable

• Intrauterine device (IUD)

• Intrauterine hormone-releasing system (IUS)

• Bilateral tubal occlusion

• Vasectomized partner

• True sexual abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar ovulation, symptothermal, post-ovulation methods) is not acceptable

‣ Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an ICF approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), and agree to abide by the study restrictions and return to the site for the required assessments, including the OS Follow-up Period.